Azarest 300 mg is a prescription medication that contains Azacitidine, a potent chemotherapeutic agent classified under nucleoside metabolic inhibitors. This medication is primarily used in the treatment of myelodysplastic syndromes (MDS) and other related bone marrow disorders, such as chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). Manufactured to the highest pharmaceutical standards, Azarest 300 mg offers a reliable and effective option for patients who require disease-modifying treatment in hematologic malignancies.

Azacitidine is a cytotoxic agent that works by incorporating into RNA and DNA, disrupting abnormal cell growth and division. It also exerts epigenetic modulation, helping to restore normal function in bone marrow cells by altering the expression of certain genes involved in cell differentiation and proliferation.

Azarest 300 mg is indicated for the treatment of adult patients with:

Myelodysplastic syndromes (MDS), including all French-American-British (FAB) subtypes

Chronic myelomonocytic leukemia (CMML)

Acute myeloid leukemia (AML) with 20–30% blasts and multilineage dysplasia

Azacitidine exerts its therapeutic effects through a dual mechanism:

Hypomethylation: By inhibiting DNA methyltransferases, Azacitidine reduces DNA methylation, reactivating tumor suppressor genes and enabling normal cell development.

Cytotoxicity: In high doses, it integrates into RNA and DNA, leading to cell cycle arrest and apoptosis of rapidly dividing cancer cells.

These combined actions make Azarest an essential drug for altering the course of hematologic malignancies, especially in patients who are not eligible for bone marrow transplantation.

Azarest 300 mg is usually administered by a healthcare professional via subcutaneous injection or intravenous infusion. The dosage and schedule depend on the patient's body surface area, disease status, and overall health. A common regimen involves daily administration for 7 consecutive days in a 28-day cycle, but dosing should always follow the specific guidance of an oncologist or hematologist.

Like all chemotherapy agents, Azarest 300 mg may cause side effects, including:

Nausea, vomiting, and diarrhea

Fatigue and weakness

Injection site reactions

Low blood cell counts (anemia, neutropenia, thrombocytopenia)

Fever and increased risk of infections

Routine blood tests are essential to monitor for hematologic toxicity and to adjust dosing accordingly.

Not recommended during pregnancy or breastfeeding due to potential harm to the fetus or infant.

Caution is advised in patients with hepatic or renal impairment.

Contraceptive measures are advised during and after treatment.

Store Azarest 300 mg at controlled room temperature, away from light and moisture. Keep out of reach of children.

Azarest 300 mg (Azacitidine) should only be used under the supervision of a qualified medical professional. Always consult your healthcare provider for personalized medical advice and before starting any new treatment regimen.